140 related articles for article (PubMed ID: 35973309)
1. Anti-epileptogenic effects of synaptic vesicle protein 2A modulation in a mouse model of Alzheimer's disease.
Silva JC; Shen Y; Chan J; Kwan P; Jones NC
Epilepsy Res; 2022 Oct; 186():106994. PubMed ID: 35973309
[TBL] [Abstract][Full Text] [Related]
2. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
[TBL] [Abstract][Full Text] [Related]
3. A mouse model of Alzheimer's disease displays increased susceptibility to kindling and seizure-associated death.
Chan J; Jones NC; Bush AI; O'Brien TJ; Kwan P
Epilepsia; 2015 Jun; 56(6):e73-7. PubMed ID: 25879152
[TBL] [Abstract][Full Text] [Related]
4. Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein.
Fukuyama K; Okada M
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562864
[TBL] [Abstract][Full Text] [Related]
5. Z944, a Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model.
Casillas-Espinosa PM; Hicks A; Jeffreys A; Snutch TP; O'Brien TJ; Powell KL
PLoS One; 2015; 10(8):e0130012. PubMed ID: 26274319
[TBL] [Abstract][Full Text] [Related]
6. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effects of Time-Limited Treatment with Brivaracetam on Posttraumatic Epilepsy after Fluid Percussion Injury in the Rat.
Eastman CL; Fender JS; Klein P; D'Ambrosio R
J Pharmacol Exp Ther; 2021 Dec; 379(3):310-323. PubMed ID: 34593559
[TBL] [Abstract][Full Text] [Related]
8. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
Gillard M; Fuks B; Leclercq K; Matagne A
Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
[TBL] [Abstract][Full Text] [Related]
9. Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model.
Stratton SC; Large CH; Cox B; Davies G; Hagan RM
Epilepsy Res; 2003 Feb; 53(1-2):95-106. PubMed ID: 12576171
[TBL] [Abstract][Full Text] [Related]
10. Loss of presenilin 2 age-dependently alters susceptibility to acute seizures and kindling acquisition.
Beckman M; Knox K; Koneval Z; Smith C; Jayadev S; Barker-Haliski M
Neurobiol Dis; 2020 Mar; 136():104719. PubMed ID: 31862541
[TBL] [Abstract][Full Text] [Related]
11. Seizure susceptibility of neuropeptide-Y null mutant mice in amygdala kindling and chemical-induced seizure models.
Shannon HE; Yang L
Epilepsy Res; 2004; 61(1-3):49-62. PubMed ID: 15451008
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models.
Leclercq K; Matagne A; Provins L; Klitgaard H; Kaminski RM
J Pharmacol Exp Ther; 2020 Jan; 372(1):11-20. PubMed ID: 31619464
[TBL] [Abstract][Full Text] [Related]
13. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
Shi J; Zhou F; Wang LK; Wu GF
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
[TBL] [Abstract][Full Text] [Related]
14. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.
Tokudome K; Okumura T; Shimizu S; Mashimo T; Takizawa A; Serikawa T; Terada R; Ishihara S; Kunisawa N; Sasa M; Ohno Y
Sci Rep; 2016 Jun; 6():27420. PubMed ID: 27265781
[TBL] [Abstract][Full Text] [Related]
15. Increased epileptogenicity in a mouse model of neurofibromatosis type 1.
Sabetghadam A; Wu C; Liu J; Zhang L; Reid AY
Exp Neurol; 2020 Sep; 331():113373. PubMed ID: 32502580
[TBL] [Abstract][Full Text] [Related]
16. No persistent effects of intracerebral curcumin administration on seizure progression and neuropathology in the kindling rat model for temporal lobe epilepsy.
Drion CM; Kooijman L; Chan D; Berkhout J; van Vliet EA; Wadman WJ; Gorter JA
Epilepsy Res; 2022 Mar; 181():106873. PubMed ID: 35180639
[TBL] [Abstract][Full Text] [Related]
17. Genetic Modulation of HSPA1A Accelerates Kindling Progression and Exerts Pro-convulsant Effects.
von Rüden EL; Wolf F; Keck M; Gualtieri F; Nowakowska M; Oglesbee M; Potschka H
Neuroscience; 2018 Aug; 386():108-120. PubMed ID: 29964156
[TBL] [Abstract][Full Text] [Related]
18. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.
Löscher W; Hönack D; Rundfeldt C
J Pharmacol Exp Ther; 1998 Feb; 284(2):474-9. PubMed ID: 9454787
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies on the effects of clinically used anticonvulsants on the oxidative stress biomarkers in pentylenetetrazole-induced kindling model of epileptogenesis in mice.
Mazhar F; Malhi SM; Simjee SU
J Basic Clin Physiol Pharmacol; 2017 Jan; 28(1):31-42. PubMed ID: 27658141
[TBL] [Abstract][Full Text] [Related]
20. An interaction study of Ocimum sanctum L. and levetiracetam in pentylenetetrazole kindling model of epilepsy.
Sarangi SC; Pattnaik SS; Katyal J; Kaleekal T; Dinda AK
J Ethnopharmacol; 2020 Mar; 249():112389. PubMed ID: 31739106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
